Senseonics Completes $92 Million Public Offering
Senseonics Holdings, Inc. has announced the closing of a public offering, raising approximately $92 million through the sale of 10.4 million shares of common stock and 8 million pre-funded warrants. The offering was facilitated by TD Cowen and Barclays as joint book-running managers, and included the full exercise of underwriters’ option for an additional 2.4 million shares. The offering was conducted under an effective registration statement with the SEC.
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of common stock were sold at a price to the public of $5.00 per share and the pre-funded warrants were sold at a purchase price of $4.999 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering were approximately $92.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Senseonics.